About this trial
The purpose of the trial is to determine the overall response rate among patients with advanced solid tumors harboring a fusion of NTRK1, NTRK2 or NTRK3 following treatment with LOXO-101.
It is a Phase II, multi-center, open-label study.
Patients with advanced solid tumors harboring a fusion of NTRK1, NTRK2 or NTRK3.
Subjects with NTRK1, NTRK2, or NTRK3 fusion-positive cancers will be identified through molecular assays as routinely performed at Clinical Laboratory Improvement Amendments of 1988 (CLIA) or other
similarly certified laboratories.
Where’s this trial being run?
St Vincents University Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.Print this page
For more detailed informationClick Here
Here’s a list of questions you may have for your doctor or local cancer research team.Questions
A Phase II Basket Study of the Oral TRK Inhibitor LOXO-101 in Subjects With NTRK Fusion-Positive Tumors
|Principal Investigator:||Prof Ray McDermott (St. Vincent's University Hospital)|
Loxo Oncology, Inc.
Global: October 2015
Ireland: September 2015
|Global Recruitment Target:||226|
|Ireland Recruitment Target:||7|